DPP4 and type 2 diabetes mellitus: In spite of this, the clinical outcomes of COVID-19 patients using DPP4 inhibitors only was not significantly different from that using both DPP4 inhibitors and RAS inhibitors and was notably improved from COVID-19 T2DM patients without medication [145].